OptiNose, Inc. is a leading pharmaceutical company in the United States specializing in developing and commercializing products for ear, nose, and throat specialists and allergy specialists. Their flagship product, XHANCE nasal spray, utilizes their innovative Exhalation Delivery System (EDS) to deliver corticosteroids for chronic rhinosinusitis with nasal polyps. OptiNose, Inc. has a high-risk rating score of 35.8 in ESG assessment.